Imke Atreya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3692664/publications.pdf

Version: 2024-02-01

623734 526287 29 797 14 27 citations g-index h-index papers 29 29 29 1269 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Differential effects of $\hat{l}\pm4\hat{l}^27$ and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut, 2016, 65, 1642-1664.	12.1	138
2	Blockade of $\hat{l}\pm\hat{l}^27$ integrin suppresses accumulation of CD8 ⁺ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut, 2017, 66, 1936-1948.	12.1	99
3	Non-classical monocyte homing to the gut via $\hat{l}\pm4\hat{l}^27$ integrin mediates macrophage-dependent intestinal wound healing. Gut, 2020, 69, 252-263.	12.1	80
4	A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2–mediated inflammation. Journal of Experimental Medicine, 2019, 216, 2763-2777.	8.5	48
5	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 508-524.	1.3	46
6	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Frontiers in Immunology, 2017, 8, 764.	4.8	42
7	Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncolmmunology, 2015, 4, e981483.	4.6	38
8	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. Journal of Clinical Investigation, 2016, 126, 611-626.	8.2	38
9	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases, 2018, 24, 1237-1250.	1.9	33
10	Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. Gastroenterology, 2017, 153, 898-900.	1.3	27
11	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 39.	3.5	25
12	Residual homing of $\hat{l}\pm4\hat{l}^27$ -expressing \hat{l}^21 (sup>+Pl16 ⁺ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut, 2022, 71, 1551-1566.	12.1	24
13	Innate lymphoid cells in intestinal cancer development. Seminars in Immunology, 2019, 41, 101267.	5.6	22
14	Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. Frontiers in Immunology, 2017, 8, 1371.	4.8	20
15	Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation. Gut, 2023, 72, 275-294.	12.1	18
16	Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases. Frontiers in Medicine, 2021, 8, 656745.	2.6	16
17	ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure. Frontiers in Immunology, 2020, 11, 691.	4.8	15
18	Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cellular and Molecular Life Sciences, 2017, 74, 803-826.	5.4	12

#	Article	IF	CITATIONS
19	Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterology, 2020, 20, 103.	2.0	12
20	Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy. Journal of Visualized Experiments, 2019, , .	0.3	11
21	Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterology, 2021, 21, 33.	2.0	10
22	Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System. Journal of Investigative Dermatology, 2022, 142, 2149-2158.e10.	0.7	7
23	Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflammatory Bowel Diseases, 2022, 28, 1746-1755.	1.9	5
24	Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. Journal of Visualized Experiments, 2018 , , .	0.3	3
25	Vedolizumab blocks $\hat{l}\pm4\hat{l}^27$ integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210988.	3.2	3
26	Editorial: Loss of Epithelial Barrier Integrity in Inflammatory Diseases: Cellular Mediators and Therapeutic Targets. Frontiers in Medicine, 2021, 8, 813153.	2.6	2
27	Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 605-620.	3.1	1
28	An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance. Journal of Visualized Experiments, 2020, , .	0.3	1
29	$\hat{l}\pm4\hat{l}^2$ 7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110547.	3.2	1